Weekly briefings only appear here after editorial review and public publish. Until the next edition clears, use the archive for recent GLP-1 signal or start with the current patient guides below.
GLP-1 medications like semaglutide and tirzepatide help women with PCOS who have obesity or insulin resistance by promoting weight loss and improving metabolic health, though their direct impact on hormonal and reproductive symptoms remains unclear and varies by individual.
Read moreWegovy is a once-weekly injection for weight management with a stepwise dose escalation from 0.25 mg to 2.4 mg over about 16 weeks to improve tolerance and minimize side effects. A higher 7.2 mg dose was FDA-approved in early 2026 but is not yet widely available. Proper injection technique, missed dose management, and ongoing clinician supervision are essential.
Read moreA plain-language breakdown of formulary tightening, prior authorization logic, and what patients are really comparing when cash pay becomes the fallback.
Read moreAcross GLP-1 communities, patients use “food noise” to describe the chatter around hunger and reward. The phrase persists because it maps onto lived experience better than a clinical label.
Full analysisGLP-1 medications like semaglutide and tirzepatide help women with PCOS who have obesity or insulin resistance by promoting weight loss and improving metabolic health, though their direct impact on hormonal and reproductive symptoms remains unclear and varies by individual.
Full analysisWe track over twenty independent publications covering obesity medicine, metabolic health, and GLP-1 treatment. The list includes clinician-scientists, specialist obesity writers, and adjacent medical voices that add context most news sources miss.
Started publishing Jun 2024
Michael Albert is one of the clearest outside reads if you want obesity medicine discussed as a serious clinical category instead of a consumer trend. He writes about access, telehealth, employers, surgery, GLP-1 care, and the difference between evidence-based treatment and weight-loss marketing. Readers who want sharp, on-topic analysis without a wellness gloss should spend time here.
Started publishing May 2024
This is one of the better specialist reads in the whole set if you want obesity treatment coverage that actually stays focused on obesity treatment. It is especially useful for guidelines, pharmacotherapy, and the policy side of clinical obesity care. Readers who want a tighter specialist lens rather than broad wellness or business coverage should start here.
Started publishing Jan 2021
Howard Luks is worth reading if you care about what happens after the first burst of weight loss. His work is especially good on exercise, muscle, mobility, and the physical tradeoffs that can get lost in more medication-centered coverage. This is a strong companion read for people trying to connect weight loss with long-term function and strength.
Every article, explainer, and company profile is built on named sources, cited research, and structured editorial review. Browse by topic or start with what other readers are finding useful.